Arecor expands its global partnerships through collaboration to develop an enhanced antibody formulation
Cambridge, UK - Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to enable healthier lives, announces that it has signed an agreement with a top 10 pharmaceutical company to develop an enhanced antibody formulation for one of its investigational drugs.
Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a novel, stable formulation of a liquid, high concentration antibody. The collaborator will fund the development work, generating new revenue for Arecor. This agreement adds to Arecor’s growing portfolio of partnerships.
Sarah Howell, Chief Executive Officer of Arecor, said: “This collaborator is a leader in the development of novel medicines. Arecor has a proven track record of leveraging its Arestat technology to help deliver these complex therapeutics. We work closely with our partners to develop more effective treatments where superior properties bring even greater benefit to patients and we look forward to working with the world-renowned R&D team.”
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 (“UK MAR”).
